Is FibroGen, Inc. overvalued or undervalued?

As of 2 March 2020, FibroGen, Inc. has moved from an expensive to a risky valuation grade. The company is currently considered overvalued, given its negative P/E ratio and other concerning financial metrics. The Price to Book Value stands at -0.15, while the EV to EBITDA is at -3.19, indicating significant financial distress and lack of profitability.
In comparison to its peers, FibroGen's valuation metrics are notably poor. For instance, CytomX Therapeutics, Inc. has an attractive P/E of 9.01 and an EV to EBITDA of 7.98, highlighting a stark contrast in financial health. Additionally, Chimerix, Inc. and aTyr Pharma, Inc. are also in a precarious position, with P/E ratios of -8.69 and -7.21, respectively. Despite FibroGen's recent stock performance showing a remarkable return of 1929.31% over the past week, this does not sufficiently mitigate the underlying valuation concerns.